论文部分内容阅读
目的观察并分析茚达特罗在中重度激素耐药型慢性阻塞性肺疾病(COPD)患者中的临床应用效果及安全性。方法对处于稳定期的中重度通气功能障碍COPD患者,对照组使用沙美特罗氟替卡松联合噻托溴铵吸入,治疗组以茚达特罗替代沙美特罗氟替卡松,观察患者用药12周后的肺功能指标、COPD评估测试(CAT)评分的变化。结果使用茚达特罗组与沙美特罗氟替卡松组在用药后12周后的FEV1和COPD评估测试(CAT评分)均有差异性改变,有统计学意义(P<0.05),用力肺活量(FVC)无统计学差异性改变(P>0.05)。结论茚达特罗联合噻托溴铵可以改善中重度激素耐药型COPD稳定期患者的肺功能,能够改善患者呼吸困难状况,提高生活质量并且有一定的安全性。
Objective To observe and analyze the clinical application and safety of indacaterol in patients with moderate-severe steroid-resistant chronic obstructive pulmonary disease (COPD). Methods In stable COPD patients with moderate-severe ventilatory dysfunction, the control group was treated with salmeterol fluticasone combined with tiotropium inhalation. The treatment group received indacaterol instead of salmeterol fluticasone, and the pulmonary function of the patients after 12 weeks of treatment Indicators, changes in COPD assessment test (CAT) score. Results The FEV1 and COPD assessment scores (CAT scores) of indacaterol and salmeterol and fluticasone groups after 12 weeks of treatment were significantly different (P <0.05) and forced vital capacity (FVC) No statistically significant difference (P> 0.05). Conclusion Indacaterol combined with tiotropium can improve lung function in patients with moderate-severe steroid-resistant COPD at stable stage, improve the patients’ breathing difficulties, improve the quality of life and have some safety.